연세대학교 산학협력단; YONSEI UNIVERSITY;INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY;INDUSTRY-ACADEMIC COOPERATION FOUNDATION
发明人:
MOON, JAE HOON,문재훈,CHA, BONG SOO,차봉수
申请号：
KR1020110078274
公开号：
KR1020130015932A
申请日:
2011.08.05
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
PURPOSE: A pharmaceutical composition containing a thiazolidinedione-based drug for preventing and treating Alzheimer's disease is provided to enhance LRP1 expression and the discharge of beta-amyloid into the blood. CONSTITUTION: A pharmaceutical composition for treating neurological disorders contains a thiazolidinedione-based drug as an active ingredient. The thiazolidinedione-based drug includes rosiglitazone, pioglitazone, or troglitazone. The pharmaceutical composition enhances the LRP1 expression level in the cerebrovascular endothelial cells. The pharmaceutical composition enhances the absorption of beta-amyloid by LRP1. The composition is a capsule, a tablet, a granule, an injection, an ointment, a powder, or a beverage. A health functional food for preventing or treating neurological disorders contains a thiazolidinedione-based drug as an active ingredient.본 발명은 치아졸리딘다이온 계열의 약제를 유효성분으로 포함하는 알츠하이머 병 예방 및 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 치아졸리딘다이온 계열의 약제를 저용량으로 사용하면 LRP1의 발현을 증가시켜, 베타아밀로이드의 뇌실질에서 혈액으로의 배출을 증가시키는 효과가 있다.
